

Received:
18 October 2018Revised:
28 March 2019Accepted:
15 April 2019<https://doi.org/10.1259/bjr.20180901>

Cite this article as:

Koszyła R, Raman S, Moiseenko V, Reinsberg SA, Toyota B, Nichol A. Dose-painted volumetric modulated arc therapy of high-grade glioma using 3,4-dihydroxy-6-¹⁸F-fluoro-L-phenylalanine positron emission tomography. *Br J Radiol* 2019; **92**: 20180901.

FULL PAPER

Dose-painted volumetric modulated arc therapy of high-grade glioma using 3,4-dihydroxy-6-¹⁸F-fluoro-L-phenylalanine positron emission tomography

^{1,2}ROBERT KOSZTYLA, PhD, ³SRINIVAS RAMAN, MD, ⁴VITALI MOISEENKO, PhD, ²STEFAN A REINSBERG, PhD, ⁵BRIAN TOYOTA, MD and ³ALAN NICHOL, MD

¹Department of Medical Physics, BC Cancer – Vancouver, Vancouver, British Columbia, Canada

²Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada

³Department of Radiation Oncology, BC Cancer – Vancouver, Vancouver, British Columbia, Canada

⁴Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, US

⁵Division of Neurosurgery, University of British Columbia, Vancouver, British Columbia, Canada

Address correspondence to: Dr Robert Koszyła

E-mail: rkoszyła@bccancer.bc.ca

Objective: To determine whether dose painting with volumetric modulated arc therapy for high-grade gliomas using 3,4-dihydroxy-6-¹⁸F-fluoro-L-phenylalanine (¹⁸F-FDOPA) positron emission tomography (PET) could achieve dose-escalated coverage of biological target volumes (BTVs) without increasing the dose to cranial organs at risk (OARs).

Methods: 10 patients with high-grade gliomas underwent CT, MRI, and ¹⁸F-FDOPA PET/CT images for post-operative radiation therapy planning. Two volumetric modulated arc therapy plans were retrospectively generated for each patient: a conventional plan with 60 Gy in 30 fractions to the planning target volume delineated on MRI and a dose-escalated plan with a maximum dose of 80 Gy in 30 fractions to BTVs. BTVs were created by thresholding ¹⁸F-FDOPA PET/CT uptake using a linear quadratic model that assumed tracer uptake was linearly

related to tumour cell density. The maximum doses and equivalent uniform doses of OARs were compared.

Results: The median volume of the planning target volume receiving at least 95% of the prescribed dose ($V_{95\%}$) was 99.6% with and 99.5% without dose painting. The median $V_{95\%}$ was >99.2% for BTVs. The maximum doses and equivalent uniform doses to the OARs did not differ significantly between the conventional and dose-painted plans.

Conclusion: Using commercially available treatment planning software, dose painting for high-grade gliomas was feasible with good BTV coverage and no significant change in the dose to OARs.

Advances in knowledge: A novel treatment planning strategy was used to achieve dose painting for gliomas with BTVs obtained from ¹⁸F-FDOPA PET/CT using a radiobiological model.

INTRODUCTION

Glioblastoma is the most common primary brain malignancy.¹ Despite aggressive multimodality management, the prognosis is poor, with median survival ranging from 15 to 21 months.^{2–4} The current treatment paradigm for glioblastoma consists of maximal safe resection, followed by radiation therapy with concurrent and adjuvant temozolimide (TMZ). Emerging data also support the use of tumour treating fields in selected patients.⁴ The standard radiation dose for non-elderly patients with glioblastoma, 60 Gy in 30 fractions, was established in the 1990s, when a randomized controlled trial demonstrated improved survival in comparison to 45 Gy in 20 fractions.⁵ Since then, a number of strategies have been tested to further escalate the prescription dose in glioblastoma, including brachytherapy,⁶ stereotactic

radiosurgery,⁷ and altered fractionation using conventional MRI.⁸ Performed in the pre-TMZ era, these trials consistently found an increase in the risk of radionecrosis, and despite a reduction in the risk of central relapse, there was no survival advantage with dose escalation. However, in the TMZ era, there is renewed optimism that dose escalation using a simultaneous integrated boost may improve outcomes⁹ and this strategy is being formally tested in the ongoing NRG Oncology BN001 trial.¹⁰

Another approach to dose escalation is to selectively target residual macroscopic or biologically aggressive disease. Positron emission tomography (PET) with amino acid tracers, such as ¹¹C-methionine (¹¹C-MET), ¹⁸F-fluoroethyltyrosine (¹⁸F-FET) and 3,4-dihydroxy-6-¹⁸F

fluoro-L-phenylalanine (^{18}F -FDOPA), can identify macroscopic residual disease because these tracers are taken up by cells using a specific amino acid transport system. Increased protein synthesis and upregulation of the amino acid transporter in the supporting vasculature of brain tumour tissue is responsible for increased amino acid transport into tumour cells. PET imaging with amino acid tracers can visualize disease that is not clearly identified on T_1 weighted MRI with gadolinium contrast enhancement and may be able to distinguish between viable tumour and oedema in regions of high signal on T_2 weighted MRI.^{11,12} It may also identify regions of elevated cellular density and higher-grade disease, which can be used to delineate a high-risk subvolume for dose escalation.¹³

With accruing evidence to suggest that PET imaging provides complementary, additional information to MRI, there has been recent interest in using a PET-guided dose escalation approach in gliomas. For example, a previous clinical trial in high-grade gliomas¹⁴ investigated dose escalation with an integrated boost to 72 Gy in 30 fractions to a target defined by a single ^{18}F -FET PET threshold. The study did not demonstrate a therapeutic benefit in comparison to historical outcomes, but it did not employ dose painting. A subsequent analysis showed that the original ^{18}F -FET PET defined tumour volume with an additional margin of 7 mm covered recurrent ^{18}F -FET PET tumour volumes.¹⁵ Other studies investigating patterns of failure in glioma also suggest that local recurrences may preferentially occur in areas of high amino acid tracer uptake.¹⁶

While clinical outcomes with uniform dose escalation in high-grade gliomas have been disappointing because of non-central relapses and radionecrosis, dose painting¹⁷ may provide an opportunity to maximize disease control, while minimizing the risk of radionecrosis. A voxel-by-voxel prescription of dose according to radiotracer uptake (dose painting by numbers)^{18–21} is an attractive method to achieve dose escalation with strong biological rationale. In this study, we investigate whether dose painting with volumetric modulated arc therapy (VMAT) for high-grade gliomas using ^{18}F -FDOPA PET can achieve dose-escalated coverage to biological tumour volumes (BTVs) without increasing the dose to cranial organs at risk (OARs) using commercially available treatment planning software.

METHODS AND MATERIALS

Patients and imaging

This study recruited 10 patients with histologically confirmed, newly diagnosed glioma. Patients were at least 18 years of age, had a contrast-enhancing mass on diagnostic brain CT or MRI that strongly suggested a diagnosis of World Health Organization Grade III or IV glioma prior to surgery, had a Karnofsky Performance Status of 70 or greater, and had a glomerular filtration rate of 60 mL/min or greater. The study excluded subjects who had indication for urgent craniotomy to relieve mass effect, had gadolinium enhancement or T_2 signal that involved the basal ganglia, had previous intracranial malignancy or any invasive malignancy unless free of disease for at least 5 years, prior cranial irradiation, were taking medication for the treatment of Parkinson's disease, or had allergies or contraindications to contrast

MRI or radiation therapy. The National Institutes of Health clinical trial identifier for this study was NCT01248754.²²

Each patient underwent CT (3 mm slice thickness), MRI and ^{18}F -FDOPA PET/CT imaging prior to post-operative radiation therapy. MRI consisted of gadolinium-enhanced T_1 weighted images with the turbo spin-echo sequence [echo time (TE) = 14 ms, pixel resolution = 1 mm, slice thickness = 3 mm] and T_2 weighted fluid attenuated inversion recovery images (TE = 97 ms, pixel resolution = 0.5 mm, slice thickness = 3 mm) obtained with a 1.5 T Siemens MAGNETOM Symphony Tim system (Siemens Healthcare, Erlangen, Germany). ^{18}F -FDOPA PET/CT images were obtained with a Siemens Biograph-16 Hi-Rez PET/CT system (Knoxville, TN). ^{18}F -FDOPA was synthesized by use of a previously published procedure.²³ Non-contrast CT and 15 min three-dimensional PET images were obtained of the brain 40 min following injection. The attenuation-corrected PET data were reconstructed using an iterative ordered-subset expectation maximization algorithm (matrix = 336×336, brain mode, zoom = 2.5, subsets = 8, iterations = 6, gaussian filter = 2 mm).

All images (planning CT, MRI, and PET/CT) were imported into Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA) and fused using the auto-matching registration algorithm. Image fusion details were described in a previous study.¹¹ The planning CT images were fused both to the MRI and the CT images PET/CT image set.

Volume delineation

Target volume and OAR delineations were imported from each patient's treated radiation therapy plan. The gross tumour volume (GTV) was the contrast-enhancing tumour on T_1 weighted MRI. The clinical target volume (CTV) was a 2 cm expansion of the union of the GTV and the surgical cavity, expanded, if necessary, to include all increased signal on T_2 weighted MRI. The planning target volume (PTV) was a 0.5 cm expansion of the CTV; it was prescribed a dose of 60 Gy in 30 fractions. The OARs used for treatment planning were: brainstem, optics_PRV [the optics planning organ at risk (OAR) volume was a 5 mm expansion of a continuous segmentation of the optic nerves and chiasm], anterior chambers, and retinas. The normal brain volume excluding the GTV (brain-GTV), the normal brain volume excluding the PTV (brain-PTV), and contralateral hippocampus contour were also generated. The following non-overlapping volumes were also defined: PTV60, the portion of the PTV that did not overlap with OARs; PTV54, the portion of the PTV that overlapped with the optics_PRV; PTV60b, the portion of the PTV that overlapped with the brainstem; and brainstem_opti and optics_opti, the portions of the brainstem and optics_PRV that did not overlap the PTV.

The ^{18}F -FDOPA PET uptake was used to generate simultaneous integrated boost volumes. A radiation oncologist delineated a dose-painting volume of interest on the ^{18}F -FDOPA PET images in consultation with a functional imaging specialist. Seven dose-painting biological target volumes (BTVs), BTV62.5, BTV65, BTV67.5, BTV70, BTV72.5, BTV75, and BTV77.5, were delineated inside this volume by using thresholds of ^{18}F -FDOPA

uptake. These volumes corresponded to discrete dose boosts of 62.5 to 77.5 Gy, in steps of 2.5 Gy. To calculate the image intensity threshold used to delineate a BTV, we used the linear quadratic model for cell survival. If an image voxel with intensity I and tumour cell density ρ receives a total dose D in $n_f = 30$ fractions, the tumour cell density ρ' that remains following irradiation is $\rho' = \rho \exp(-\alpha D - \beta D^2/n_f)$. If we assume that image intensity and tumour cell density were linearly related ($I = b_1\rho + b_0$), then:

$$I = b_1\rho' \exp(\alpha D + \beta D^2/n_f) + b_0 \quad (1)$$

where b_0 and b_1 are constants.

The radiobiologic parameters for glioma were $\alpha = 0.06 \text{ Gy}^{-1}$ and $\beta = 0.006 \text{ Gy}^{-2}$ ($\alpha/\beta = 10 \text{ Gy}$).²⁴ If a minimum dose 60 Gy is prescribed to an image intensity I_{\min} , a maximum dose 80 Gy is prescribed to an image intensity I_{\max} , and we required the number of surviving number of tumour cells in each voxel to be the same (ρ' is constant), then the equation for image intensity threshold was:

$$I = 0.00276 (I_{\max} - I_{\min}) \exp(\alpha D + \beta D^2/n_f) + 1.208I_{\min} - 0.208I_{\max} \quad (2)$$

Previous studies using directed brain biopsies have consistently detected glioma cells in brain regions that exhibit ¹⁸F-FDOPA tracer uptake larger than the uptake of the contralateral basal ganglia.^{25,26} Thus, we chose to biologically escalate dose in the subvolumes of the dose-painting region of interest where the PET image intensity was higher than the PET image intensity at the anatomic border of the basal ganglia, as determined from the fused planning MRI. Figure 1 shows the target volumes delineated for a glioblastoma patient.

Radiation therapy planning


Two VMAT plans were generated for each patient: a conventional plan without dose escalation delivering 95–110% of 60 Gy in 30 fractions to the PTV and a plan with dose escalation up to a maximum dose of 80 Gy. Plans were generated with the Eclipse (Varian Medical Systems Inc. Palo Alto, CA) treatment planning software using the Anisotropic Analytical Algorithm (v. 11.031) for dose calculations and Progressive Resolution Optimization for VMAT optimization. Plans were obtained using two 360° arcs of a 6 MV photon beam from a Varian TrueBeam linear accelerator with High Definition 120-leaf multileaf collimator. The plans were generated using the objectives shown in Table 1.

Evaluation of treatment plans

Cumulative dose–volume histograms (DVHs) were calculated for all target volumes and OARs for both plans for all patients. The volume of each target volume that received a dose of at least 95% of its prescribed dose ($V_{95\%}$) was recorded. For each OAR in each plan, the maximum dose and the equivalent uniform dose (EUD) were calculated. The EUD was calculated using the equation²⁷:

$$\text{EUD} = \left(\sum_{i=1}^N v_i \text{NTD}_i^{1/n} \right)^n \quad (5)$$

Figure 1. Target volumes shown on (a) CT, (b) T_1 weighted MRI, and (c) ¹⁸F-FDOPA PET for a patient with a glioblastoma. The window and level of the PET image are chosen to highlight the BTVs. Panel (d) shows a close up of panel (c). ¹⁸F-FDOPA, 3,4-dihydroxy-6-[¹⁸F]fluoro-L-phenylalanine; BTVs, biological target volumes.



where n was the volume dependence parameter,^{28–30} v_i is the relative volume of a structure that receives a normalized total dose of NTD_i , and the normalized total dose was calculated using the equation:

$$\text{NTD} = D \left(\frac{\alpha/\beta + D/n_f}{\alpha/\beta + 2\text{Gy}} \right) \quad (6)$$

with $\alpha/\beta = 2 \text{ Gy}$ for all OARs.³¹ Statistical comparisons were performed using the two-sided paired Wilcoxon sign-rank test ($\alpha = 0.05$).

RESULTS

Table 2 shows patient characteristics for this study. The median PTV60 volume was 391 cm³ (range, 251–651 cm³) and the median dose escalation volume was 25 cm³ (7–110 cm³). The PTV overlapped with the brainstem in one patient and optics_PTV in four patients. It was possible to produce dose-painted plans for all cases without sacrificing target coverage (Table 3). The median volume of the PTV60 receiving 95% of the prescribed dose ($V_{95\%}$) was 99.5% (94.9–99.9%) for conventional plans and 99.6% (95.0–100.0%) for dose-painted plans ($p = 0.5$). Figure 2 shows an example of the dose distribution for the conventional and dose-painted plans for a sample patient. Figure 3(a) shows sample target volume DVHs.

Table 1. Dose–volume histogram constraints used for volumetric modulated arc therapy.

Structure	Constraint	
	Conventional plan	Dose painting plan
PTV54	$V_{51.3 \text{ Gy}} \geq 98\%$ and $V_{54 \text{ Gy}} \leq 1\%$	$V_{51.3 \text{ Gy}} \geq 98\%$ and $V_{54 \text{ Gy}} \leq 1\%$
PTV60	$V_{95\%} \geq 98\%$ and $D_{\max} \leq 110\%$	$V_{95\%} \geq 98\%$ and $D_{\max} \leq 110\%$ for PTV60 outside of BTVs
PTV60b	$V_{95\%} \geq 98\%$ and $D_{\max} \leq 60 \text{ Gy}$	$V_{95\%} \geq 98\%$ and $D_{\max} \leq 60 \text{ Gy}$
Optics_PRV	$V_{54 \text{ Gy}} \leq 1\%$	$V_{54 \text{ Gy}} \leq 1\%$
Brainstem	$D_{\max} \leq 60 \text{ Gy}$	$D_{\max} \leq 60 \text{ Gy}$
Retina	$D_{\max} \leq 45 \text{ Gy}$	$D_{\max} \leq 45 \text{ Gy}$
Anterior chamber	$D_{\max} \leq 10 \text{ Gy}$	$D_{\max} \leq 10 \text{ Gy}$
BTV62.5	—	$V_{59.3 \text{ Gy}} \geq 95\%$
BTV65	—	$V_{61.8 \text{ Gy}} \geq 95\%$
BTV67.5	—	$V_{64.1 \text{ Gy}} \geq 95\%$
BTV70	—	$V_{66.5 \text{ Gy}} \geq 95\%$
BTV72.5	—	$V_{68.9 \text{ Gy}} \geq 95\%$
BTV75	—	$V_{71.3 \text{ Gy}} \geq 95\%$
BTV77.5	—	$V_{73.6 \text{ Gy}} \geq 95\%$ and $D_{\max} \leq 80 \text{ Gy}$

V_x is the percentage volume of a structure that received a dose of x or greater. BTV, biological target volumes; D_{\max} = maximum dose; PTV, planning target volume.

Table 4 shows the comparison of maximum dose and EUD of each OAR for conventional plans and dose-painted plans. In all plans, there was no statistically significant difference in the maximum dose or EUD for the optics, brainstem, retina, and anterior chamber. Similar DVHs were obtained for all OARs

for both conventional and dose-painted plans (Figure 3(b)). The maximum dose in the brain–PTV and contralateral hippocampus was not statistically different between conventional and dose painting plans. While dose escalation led to a small, but statistically significant increase of the brain–PTV and brain–GTV EUD, the contralateral hippocampus EUD was not significantly different between plans.

Table 2. Patient characteristics

Number of patients	10
Sex	
Female	4 (40%)
Male	6 (60%)
Age, median (range)	56 (19–80)
Histology	
Anaplastic astrocytoma	1 (10%)
Anaplastic oligodendroglioma	1 (10%)
Glioblastoma	8 (80%)
Extent of resection ^a	
Gross total resection	4 (40%)
Partial resection	4 (40%)
Biopsy only	2 (20%)
Time, median (range)	
Surgery to MRI	19 (2–35)
Pre-op PET/CT to surgery	7 (5–7)
Surgery to post-op PET/CT	31 (18–41)

PET, positron emission tomography.

^aExtent of resection was judged with gadolinium contrast on T_1 weighted MRI.

DISCUSSION

This study has shown that dose painting with ^{18}F -FDOPA PET-defined BTV contours was feasible using commercially available planning software without increasing the dose delivered to cranial OARs. By delivering higher doses to regions with a greater burden of disease, as identified with the ^{18}F -FDOPA tracer, we expect that this technique would offer better disease control than conventional radiotherapy for high-grade gliomas.

This dose painting method relied on experimentally derived radiobiological parameters for the assignment of dose painting thresholds. Qi et al²⁴ reported large variations in the radiosensitivity and repair parameters for gliomas: $\alpha = 0.06 \pm 0.05 \text{ Gy}^{-1}$ and $\alpha/\beta = 10.0 \pm 15.1 \text{ Gy}$. The choice of these values is important in optimizing the therapeutic ratio and further research is needed to determine the appropriate parameters to use in this model. A subsequent analysis is warranted to determine how variation of α and β in the range reported by Qi et al²⁴ may affect boost volumes. In the future, genomic assays of radiosensitivity may provide the necessary radiobiological data for optimal dose escalation of individual gliomas.³² Previous planning studies^{33,34} reported dose painting by numbers for gliomas using linear models to map image intensity or standardized uptake value to dose. Our model improved on this approach

Table 3. $V_{95\%}$ and mean dose for target volumes for conventional VMAT plans and dose-painted plans

Structure	$V_{95\%}$ (%)			Mean dose (Gy)		
	Conventional	Dose painting	<i>p</i>	Conventional	Dose painting	<i>p</i>
PTV60	99.5 (94.9–99.9)	99.6 (95.0–100.0)	0.5	60.0 (59.8–61.5)	60.0 (59.6–61.3)	0.5
BTV62.5	—	100.0 (98.2–100.0)	—	—	62.7 (61.8–63.6)	—
BTV65	—	99.9 (89.6–100.0)	—	—	64.4 (63.6–64.9)	—
BTV67.5	—	99.8 (74.7–100.0)	—	—	66.4 (65.1–67.2)	—
BTV70	—	99.2 (61.0–100.0)	—	—	68.7 (66.9–69.3)	—
BTV72.5	—	99.7 (61.5–100.0)	—	—	71.1 (69.4–72.2)	—
BTV75	—	99.7 (83.2–100.0)	—	—	74.1 (72.6–75.2)	—
BTV77.5	—	99.9 (98.8–100.0)	—	—	76.3 (75.4–77.7)	—

BTV, biological target volume; PTV, planning target volume; VMAT, volumetric modulated arc therapy. Median values are shown with the range in parentheses.

by mapping image intensity to dose by using a radiobiological model.

This study has a few limitations, such as the small number of patients ($n = 10$). In addition, it did not include patients with tumours near the basal ganglia since there is intense normal uptake of ^{18}F -FDOPA in these structures, which decreases the contrast ratio that required for robust dose painting techniques. While other amino acid tracers (^{11}C -MET and

^{18}F -FET) do not have this limitation, ^{18}F -FDOPA has its own advantages including a longer half-life compared to ^{11}C -MET and superior contrast ratios outside the striatum compared to ^{18}F -FET, and is felt to perform comparably to other radio-tracers in imaging malignant gliomas.^{35–37} In addition, post-surgical changes around the resection cavity can exhibit tracer uptake because of high levels of amino acid transport by activated macrophages or ^{18}F -FDOPA leakage due to disruption of the blood–brain barrier.²⁶ This challenge was partially

Figure 2. Isodose lines are shown for (a–c) conventional volumetric modulated arc therapy plans and (d–f) dose-painted plans on transverse, coronal, and sagittal CT images.




Figure 3. Panel (a) shows the DVHs for the PTV without dose escalation (solid lines) and the PTV and BTVs with dose painting (dashed lines) for a sample patient. Panel (b) shows DVHs for organs at risk for plans without dose escalation (solid lines) and with dose painting (dashed lines) for the same sample patient. BTVs, biological target volumes; DVH, dose-volume histogram; PTV, planning target volume.




Table 4. Dosimetric comparison of organs at risk for conventional volumetric modulated arc therapy plans and dose-painted plans

Structure	Maximum dose (Gy)			EUD (Gy)			
	Conventional	Dose painting	<i>p</i>	Conventional	Dose painting	<i>p</i>	<i>n</i>
Optics_PRV	16.7 (5.2–53.6)	14.2 (5.3–53.7)	0.9	5.6 (1.5–35.0)	5.4 (1.6–33.8)	0.6	0.25
Brainstem	53.4 (13.1–59.8)	53.1 (12.9–59.4)	0.05	31.6 (2.9–46.2)	31.8 (2.9–46.6)	0.9	0.16
Retina	7.8 (2.0–34.8)	6.9 (1.9–32.6)	0.05	2.7 (0.7–12.1)	2.7 (0.7–11.8)	0.14	0.2
Anterior chamber	6.2 (1.6–8.9)	6.1 (1.5–9.5)	0.14	2.0 (0.7–3.4)	2.1 (0.7–3.3)	0.6	0.3
Brain-GTV	62.7 (62.6–64.5)	76.9 (66.8–79.0)	0.002	44.1 (37.0–48.9)	44.2 (36.5–49.1)	0.03	0.25
Brain-PTV	61.1 (59.2–62.3)	61.6 (59.7–62.7)	0.10	31.9 (25.8–35.3)	33.3 (26.9–36.6)	0.006	0.25
Contralateral hippocampus	51.8 (10.5–61.6)	50.9 (10.2–62.2)	0.7	30.8 (2.7–54.1)	31.5 (2.6–54.5)	0.4	0.25

GTV, gross tumour volume; PTV, planning target volume.

Median values are shown with the range in parentheses. *n* is the volume dependence parameter used for EUD calculations.

mitigated by having a radiation oncologist, with experience in contouring on ¹⁸F-FDOPA PET images, delineate volumes of interest for dose escalation in consultation with a functional imaging specialist. Another issue is that our radiobiological modelling was informed by limited knowledge about the precise relationship between ¹⁸F-FDOPA tracer uptake and tumour cell density.^{38,39} Greater knowledge about the relationship between ¹⁸F-FDOPA tracer standardized uptake values and tumour cell density for high-grade gliomas might justify maximum dose escalation over 80 Gy in some patients and less than 80 Gy in other patients. The current study utilized an 80 Gy maximum dose escalation threshold in keeping with the maximum dose criterion in the experimental arm of the NRG BN001 trial ($D_{0.03cc} \leq 80$ Gy). This maximum dose was chosen to not increase the risk of radionecrosis compared to previous clinical trials.⁴⁰⁻⁴²

This study assumed that the efficacy of radiotherapy is only correlated with the density of glioma cells. It is known that other biological parameters such as hypoxia affect radiotherapy efficacy and it is not always correlated to cell density. This is particularly of importance in glioblastoma, where hypoxia has well-established role in radioresistance and tumour progression.^{43,44} Imaging biomarkers able to evaluate the level of hypoxia such as ¹⁸F-fluoromisonidazole and ¹⁸F-flortanidazole PET may be useful for dose escalation.^{45,46} In addition, ¹⁸F-fluorothymidine PET has been correlated to cellular markers of cell proliferation in glioma⁴⁷ and may translate clinically into individualized treatments for glioma.⁴⁸

The impact of PET image acquisition parameters and reconstruction algorithms on dose painting by contours also needs to be established. Correction of the partial volume effect is important. The prescribed dose escalation in this study could occur over small distances (Figure 1(d)) and the partial volume effect could greatly impact delineation of the dose escalation contours. BTVs

generated with the radiobiological model used in this study could result in small boost volumes with high dose gradients that are not necessarily physically achievable.

This dosimetric planning study includes no clinical outcomes or toxicity data and a prospective clinical trial is required to demonstrate the efficacy and safety of the dose painting method investigated in this study. While dose escalation volumes can be delineated manually in commercial treatment planning software, scripts that automatically delineate BTVs would be beneficial for standardizing delineations if multiple centers are involved. A dose-exploration trial could test different levels of dose escalation for different levels of PET uptake across multiple patients. On-treatment and post-treatment PET/CT imaging could be obtained to assess the change of PET tracer uptake at various dose levels. The changes in uptake between the pre-treatment, on-treatment and post-treatment PET scans could be compared to provide three-dimensional dose-response information in high-grade gliomas. This information would be valuable for further optimization of the dose painting algorithm.

CONCLUSIONS

Using a commercially available VMAT treatment planning system, it was feasible to generate dose painted-by-contour plans for BTV contours that were generated by thresholding ¹⁸F-FDOPA PET images of high-grade gliomas. Further study is planned to investigate the clinical impact of the proposed dose-painting technique.

FUNDING

This work was funded in part by a Natural Sciences and Engineering Research Council of Canada Alexander Graham Bell Canada Graduate Scholarship (to RK), the Brain Tumour Foundation of Canada, and the BC Cancer Foundation - Hershey and Yvette Porte Neuro-Oncology Endowment Fund.

REFERENCES

- Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. *Neuro Oncol* 2016; **18**(Suppl 5): v1-75. doi: <https://doi.org/10.1093/neuonc/now207>
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005; **352**: 987-96. doi: <https://doi.org/10.1056/NEJMoa043330>
- Pan I-W, Ferguson SD, Lam S. Patient and treatment factors associated with survival among adult glioblastoma patients: a USA population-based study from 2000-2010. *J Clin Neurosci* 2015; **22**: 1575-81. doi: <https://doi.org/10.1016/j.jocn.2015.03.032>
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA* 2017; **318**: 2306-16. doi: <https://doi.org/10.1001/jama.2017.18718>
- Bleehen NM, Stenning SP. A medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The medical Research Council Brain Tumour Working Party. *Br J Cancer* 1991; **64**: 769-74.
- Barbarite E, Sick JT, Berchmans E, Bregy A, Shah AH, Elsawyad N, et al. The role of brachytherapy in the treatment of glioblastoma multiforme. *Neurosurg Rev* 2017; **40**: 195-211. doi: <https://doi.org/10.1007/s10143-016-0727-6>
- Shah JL, Li G, Shaffer JL, Azoulay MI, Gibbs IC, Nagpal S, et al. Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma. *Neurosurgery* 2018; **82**: 24-34. doi: <https://doi.org/10.1093/neuros/nyx115>
- Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M. Radiotherapy for high-grade gliomas. does altered fractionation improve the outcome? *Strahlenther Onkol* 2004; **180**: 401-7. doi: <https://doi.org/10.1007/s00066-004-1220-7>

9. Tsien CI, Brown D, Normolle D, Schipper M, Pierr M, Junck L, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. *Clin Cancer Res* 2012; **18**: 273–9. doi: <https://doi.org/10.1158/1078-0432.CCR-11-2073>
10. NRG Oncology. Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma. In: *ClinicalTrials.gov*; 2018. <https://clinicaltrials.gov/ct2/show/NCT02179086>.
11. Kosztyla R, Chan EK, Hsu F, Wilson D, Ma R, Cheung A, et al. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers. *Int J Radiat Oncol Biol Phys* 2013; **87**: 1100–6. doi: <https://doi.org/10.1016/j.ijrobp.2013.09.008>
12. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology Working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol* 2016; **18**: 1199–208. doi: <https://doi.org/10.1093/neuonc/now058>
13. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-dopa PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. *Neuro Oncol* 2013; **15**: 1058–67. doi: <https://doi.org/10.1093/neuonc/not002>
14. Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. *Strahlenther Onkol* 2012; **188**: 334–9. doi: <https://doi.org/10.1007/s00066-011-0060-5>
15. Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, et al. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. *Radiat Oncol* 2016; **11**: 87. doi: <https://doi.org/10.1186/s13014-016-0665-z>
16. Lundemann M, Costa JC, Law I, Engelholm SA, Muhic A, Poulsen HS, et al. Patterns of failure for patients with glioblastoma following O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. *Radiother Oncol* 2017; **122**: 380–6. doi: <https://doi.org/10.1016/j.radonc.2017.01.002>
17. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. *Int J Radiat Oncol Biol Phys* 2000; **47**: 551–60. doi: [https://doi.org/10.1016/S0360-3016\(00\)00467-3](https://doi.org/10.1016/S0360-3016(00)00467-3)
18. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. *Lancet Oncol* 2005; **6**: 112–7. doi: [https://doi.org/10.1016/S1470-2045\(05\)01737-7](https://doi.org/10.1016/S1470-2045(05)01737-7)
19. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. *Semin Radiat Oncol* 2011; **21**: 101–10. doi: <https://doi.org/10.1016/j.semradonc.2010.10.001>
20. Rasmussen JH, Håkansson K, Vogelius IR, Aznar MC, Fischer BM, Friborg J, et al. Phase I trial of 18F-Fluoroxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. *Radiother Oncol* 2016; **120**: 76–80. doi: <https://doi.org/10.1016/j.radonc.2016.03.005>
21. Grönlund E, Johansson S, Montelius A, Ahnesjö A. Dose painting by numbers based on retrospectively determined recurrence probabilities. *Radiother Oncol* 2017; **122**: 236–41. doi: <https://doi.org/10.1016/j.radonc.2016.09.007>
22. Nichol A. Positron emission tomography (PET) with 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) study. In: *ClinicalTrials.gov*; 2018. <https://clinicaltrials.gov/ct2/show/NCT01248754>.
23. Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation with [¹⁸F]F2 and [¹⁸F]CH₃COOF: a high yield synthesis of 6-[¹⁸F]Fluoro-L-dopa. *Int J Rad Appl Instrum A* 1992; **43**: 989–96. doi: [https://doi.org/10.1016/0883-2889\(92\)90217-3](https://doi.org/10.1016/0883-2889(92)90217-3)
24. Qi XS, Schultz CJ, Li XA. An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. *Int J Radiat Oncol Biol Phys* 2006; **64**: 1570–80. doi: <https://doi.org/10.1016/j.ijrobp.2005.12.022>
25. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, et al. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. *J Nucl Med* 2012; **53**: 393–8. doi: <https://doi.org/10.2967/jnumed.111.095711>
26. Chen W, Silverman DHS, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. *J Nucl Med* 2006; **47**: 904–11.
27. Allen Li X, Alber M, Deasy JO, Jackson A, Ken Jee K-W, Marks LB, et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics Committee of the AAPM. *Med Phys* 2012; **39**: 1386–409. doi: <https://doi.org/10.1118/1.3685447>
28. Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. *Int J Radiat Oncol Biol Phys* 2010; **76**(3 Suppl): S36–S41. doi: <https://doi.org/10.1016/j.ijrobp.2009.08.078>
29. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. *Int J Radiat Oncol Biol Phys* 2010; **76**(3 Suppl): S28–S35. doi: <https://doi.org/10.1016/j.ijrobp.2009.07.1753>
30. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. *Int J Radiat Oncol Biol Phys* 1991; **21**: 123–35. doi: [https://doi.org/10.1016/0360-3016\(91\)90172-Z](https://doi.org/10.1016/0360-3016(91)90172-Z)
31. Wigg D. *Applied Radiobiology and Bioeffect Planning*. Madison, WI: Medical Physics Publishing; 2001.
32. Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *Lancet Oncol* 2017; **18**: 202–11. doi: [https://doi.org/10.1016/S1470-2045\(16\)30648-9](https://doi.org/10.1016/S1470-2045(16)30648-9)
33. Rickhey M, Morávek Z, Eilles C, Koelbl O, Bogner L. 18F-FET-PET-based dose painting by numbers with protons. *Strahlenther Onkol* 2010; **186**: 320–6. doi: <https://doi.org/10.1007/s00066-010-2014-8>
34. Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. *Strahlenther Onkol* 2008; **184**: 536–42. doi: <https://doi.org/10.1007/s00066-008-1883-6>
35. Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors. *Neuro Oncol* 2014; **16**: 434–40. doi: <https://doi.org/10.1093/neuonc/not199>
36. Becherer A, Karanikas G, Szabó M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [¹⁸F]fluorodopa and [¹¹C]methionine. *Eur J Nucl Med Mol Imaging* 2003; **30**: 1561–7. doi: <https://doi.org/10.1007/s00259-003-1259-1>
37. Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, et al. Increasing feasibility and utility of (18)F-FDOPA PET for the

- management of glioma. *Nucl Med Biol* 2015; **42**: 788–95. doi: <https://doi.org/10.1016/j.nucmedbio.2015.06.001>
38. Jung T-Y, Jung S, Kim I-Y, Moon K-S, Jang W-Y, Park S-J, et al. Pathologic analysis of glioblastoma via multiple stereotactic biopsies of active tumor and necrosis. *Oncol Rep* 2012; **27**: 707–13. doi: <https://doi.org/10.3892/or.2011.1522>
39. Valentini MC, Mellai M, Annovazzi L, Melcarne A, Denysenko T, Cassoni P, et al. Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma. *Oncotarget* 2017; **8**: 91636–53. doi: <https://doi.org/10.18632/oncotarget.21482>
40. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy Oncology Group 93-05 protocol. *Int J Radiat Oncol Biol Phys* 2004; **60**: 853–60. doi: <https://doi.org/10.1016/j.ijrobp.2004.04.011>
41. Pollom EL, Fujimoto D, Wynne J, Seiger K, Modlin LA, Jacobs LR, et al. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. *Int J Radiat Oncol Biol Phys* 2017; **98**: 123–30. doi: <https://doi.org/10.1016/j.ijrobp.2017.01.242>
42. Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, et al. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: radiation therapy Oncology Group trial 98-03. *Int J Radiat Oncol Biol Phys* 2009; **73**: 699–708. doi: <https://doi.org/10.1016/j.ijrobp.2008.05.034>
43. Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM, et al. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. *Future Oncol* 2010; **6**: 1591–601. doi: <https://doi.org/10.2217/fon.10.123>
44. Bar EE. Glioblastoma, cancer stem cells and hypoxia. *Brain Pathol* 2011; **21**: 119–29. doi: <https://doi.org/10.1111/j.1750-3639.2010.00460.x>
45. Lindblom E, Dasu A, Uhrdin J, Even A, van Elmpt W, Lambin P, et al. Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function. *Acta Oncol* 2017; **56**: 819–25. doi: <https://doi.org/10.1080/0284186X.2017.1293289>
46. Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans J-M, et al. 18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. *Eur J Nucl Med Mol Imaging* 2017; **44**: 1383–92. doi: <https://doi.org/10.1007/s00259-017-3677-5>
47. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. *J Nucl Med* 2006; **47**: 1612–21.
48. Corroyer-Dulmont A, Pérès EA, Gérault AN, Savina A, Bouquet F, Divoux D, et al. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. *Eur J Nucl Med Mol Imaging* 2016; **43**: 682–94. doi: <https://doi.org/10.1007/s00259-015-3225-0>